129 related articles for article (PubMed ID: 34298212)
41. Sentinel lymph node biopsy alone has no adverse impact on the survival of patients with breast cancer.
Takei H; Suemasu K; Kurosumi M; Horii Y; Ninomiya J; Yoshida M; Hagiwara Y; Inoue K; Tabei T
Breast J; 2006; 12(5 Suppl 2):S157-64. PubMed ID: 16958996
[TBL] [Abstract][Full Text] [Related]
42. Axillary staging prior to or after neoadjuvant systemic therapy? A single institutional experience.
Al Mushawah F; Tan MC; Margenthaler JA
J Surg Oncol; 2010 Oct; 102(5):404-7. PubMed ID: 20082352
[TBL] [Abstract][Full Text] [Related]
43. Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial.
Canavese G; Catturich A; Vecchio C; Tomei D; Gipponi M; Villa G; Carli F; Bruzzi P; Dozin B
Ann Oncol; 2009 Jun; 20(6):1001-7. PubMed ID: 19174453
[TBL] [Abstract][Full Text] [Related]
44. Breast cancer hormone receptor negativity, triple-negative type, mastectomy and not receiving adjuvant radiotherapy were associated with axillary recurrence after sentinel lymph node biopsy.
Sekine C; Nakano S; Mibu A; Otsuka M; Oinuma T; Takeyama H
Asian J Surg; 2020 Jan; 43(1):148-153. PubMed ID: 31153730
[TBL] [Abstract][Full Text] [Related]
45. Sentinel lymph node biopsy indications and controversies in breast cancer.
Wiatrek R; Kruper L
Maturitas; 2011 May; 69(1):7-10. PubMed ID: 21411254
[TBL] [Abstract][Full Text] [Related]
46. Advantages of preoperative localization and surgical resection of metastatic axillary lymph nodes using magnetic seeds after neoadjuvant chemotherapy in breast cancer.
Mariscal Martínez A; Vives Roselló I; Salazar Gómez A; Catanese A; Pérez Molina M; Solà Suarez M; Pascual Miguel I; Blay Aulina L; Ríos Gozálvez C; Julián Ibáñez JF; Rodríguez Martínez P; Martínez Román S; Margelí Vila M; Luna Tomás MA
Surg Oncol; 2021 Mar; 36():28-33. PubMed ID: 33285433
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness analyses demonstrate that observation is superior to sentinel lymph node biopsy for postmenopausal women with HR + breast cancer and negative axillary ultrasound.
McEvoy AM; Poplack S; Nickel K; Olsen MA; Ademuyiwa F; Zoberi I; Odom E; Yu J; Chang SH; Gillanders WE
Breast Cancer Res Treat; 2020 Sep; 183(2):251-262. PubMed ID: 32651755
[TBL] [Abstract][Full Text] [Related]
48. The role of sentinel node biopsy in male breast cancer.
Maráz R; Boross G; Pap-Szekeres J; Markó L; Rajtár M; Ambrózay É; Bori R; Cserni G
Breast Cancer; 2016 Jan; 23(1):85-91. PubMed ID: 24794951
[TBL] [Abstract][Full Text] [Related]
49. National Trend of Axillary Management in Clinical T3/T4 N0 Patients Having Breast Conserving Therapy.
Morris MC; Lee TC; Johnston ME; Hanseman D; Lewis JD; Shaughnessy EA; Reyna C
J Surg Res; 2020 Nov; 255():361-370. PubMed ID: 32599456
[TBL] [Abstract][Full Text] [Related]
50. Using the axillary reverse mapping technique to screen breast cancer patients with a high risk of lymphedema.
Liu S; Wang N; Gao P; Liu P; Yang H; Xie F; Wang S; Liu M; Wang S
World J Surg Oncol; 2020 Jun; 18(1):118. PubMed ID: 32482174
[TBL] [Abstract][Full Text] [Related]
51. Current trends of sentinel lymph node biopsy for breast cancer--a surgeon's perspective.
Takei H; Kurosumi M; Yoshida T; Ninomiya J; Hagiwara Y; Kamimura M; Hayashi Y; Tozuka K; Suemasu K; Inoue K; Tabei T
Breast Cancer; 2007; 14(4):362-70. PubMed ID: 17986801
[TBL] [Abstract][Full Text] [Related]
52. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements.
McLaughlin SA; Wright MJ; Morris KT; Giron GL; Sampson MR; Brockway JP; Hurley KE; Riedel ER; Van Zee KJ
J Clin Oncol; 2008 Nov; 26(32):5213-9. PubMed ID: 18838709
[TBL] [Abstract][Full Text] [Related]
53. Surgical Management of the Axilla of HER2+ Breast Cancer in the Z1071 Era: A Propensity-Score-Matched Analysis of the NCDB.
Naffouje SA; Sabesan A; Hoover SJ; Lee MC; Laronga C
Ann Surg Oncol; 2021 Dec; 28(13):8777-8788. PubMed ID: 34258723
[TBL] [Abstract][Full Text] [Related]
54. Sentinel lymph node biopsy (SLNB) vs. axillary lymph node dissection (ALND) in the current surgical treatment of early stage breast cancer.
Gherghe M; Bordea C; Blidaru A
J Med Life; 2015; 8(2):176-80. PubMed ID: 25866575
[TBL] [Abstract][Full Text] [Related]
55. Intraoperative palpation of sentinel lymph nodes can accurately predict axilla in early breast cancer.
Ozkurt E; Yardımcı E; Tükenmez M; Ersoy YE; Yilmaz R; Cabioğlu N; Karanlık H; Kulle CB; Malya FU; Önder S; Gucin Z; İğci A; Özmen V; Dinççağ AS; Müslümanoğlu M
Breast J; 2019 Jan; 25(1):96-102. PubMed ID: 30419607
[TBL] [Abstract][Full Text] [Related]
56. Management of sentinel node re-mapping in patients who have second or recurrent breast cancer and had previous axillary procedures.
Tokmak H; Kaban K; Muslumanoglu M; Demirel M; Aktan S
World J Surg Oncol; 2014 Jul; 12():205. PubMed ID: 25016393
[TBL] [Abstract][Full Text] [Related]
57. Probability of axillary lymph node metastasis when sentinel lymph node biopsy is negative in women with clinically node negative breast cancer: a Bayesian approach.
Okamoto T; Yamazaki K; Kanbe M; Kodama H; Omi Y; Kawamata A; Suzuki R; Igari Y; Tanaka R; Iihara M; Ito Y; Sawada T; Nishikawa T; Maki M; Kusakabe K; Mitsuhashi N; Obara T
Breast Cancer; 2005; 12(3):203-10. PubMed ID: 16110290
[TBL] [Abstract][Full Text] [Related]
58. Arm lymphoedema after axillary surgery in women with invasive breast cancer.
Sackey H; Magnuson A; Sandelin K; Liljegren G; Bergkvist L; Fülep Z; Celebioglu F; Frisell J
Br J Surg; 2014 Mar; 101(4):390-7. PubMed ID: 24536010
[TBL] [Abstract][Full Text] [Related]
59. Does Axillary Reverse Mapping Prevent Lymphedema After Lymphadenectomy?
Tummel E; Ochoa D; Korourian S; Betzold R; Adkins L; McCarthy M; Hung S; Kalkwarf K; Gallagher K; Lee JY; Klimberg VS
Ann Surg; 2017 May; 265(5):987-992. PubMed ID: 27163955
[TBL] [Abstract][Full Text] [Related]
60. Validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Preliminary results.
Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
Surg Oncol; 2019 Sep; 30():52-57. PubMed ID: 31500785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
